Department of Health Sciences, Northeastern University, Boston, Massachusetts, USA
African Centre for Community Investment in Health, Nginyang, Kenya.
BMJ Open. 2024 Jul 11;14(7):e085636. doi: 10.1136/bmjopen-2024-085636.
The leishmaniases are among the group of neglected tropical diseases that cause significant morbidity and mortality each year. Currently, the East Africa region has the highest visceral leishmaniasis burden in the world. Ethiopia is one of the East African countries that reports both visceral and cutaneous forms of the disease. As part of the Nairobi Declaration, Ethiopia showed commitment to the elimination of visceral leishmaniasis by 2030. In this endeavour, it is important to understand the scope of research conducted on leishmaniases in the country and identify where the research gaps exist. Determining the research landscape is vital in the plan towards leishmaniases control and elimination. It will help to reference conducted research, determine if systematic reviews are warranted and help prioritise future research directions.
This protocol was developed with reference to the JBI Scoping Review Methodology Group's guidance on conducting scoping reviews and the PRISMA-ScR reporting guidelines for scoping reviews. The following databases will be searched: PubMed, Embase via Embase.com, Web of Science Core Collection, Cochrane CENTRAL, Global Index Medicus, ClinicalTrials.gov, the Pan African Clinical Trials Registry and PROSPERO. Locally published literature that may not be indexed in the above-mentioned systems will be identified through team members familiar with the setting. Each record will be dually and blindly reviewed in an abstract-title screen and full-text screen using inclusion-exclusion criteria. Included articles must contain an in-depth discussion of leishmaniasis in Ethiopia. Data extracted will consist of study themes, study types, and categories and subcategories each defined in the developed codebook, in addition to type of leishmania, year of publication, funding source and the number of citations. Results will be reported with summary statistics.
Individual consenting and ethical approvals are not applicable. We plan to disseminate our findings to the appropriate stakeholders.
利什曼病是被忽视的热带病之一，每年都会导致大量的发病率和死亡率。目前，东非地区是世界上内脏利什曼病负担最高的地区。埃塞俄比亚是报告内脏和皮肤利什曼病的东非国家之一。作为《内罗毕宣言》的一部分，埃塞俄比亚承诺到 2030 年消除内脏利什曼病。在这一努力中，了解该国开展的利什曼病研究范围并确定研究空白非常重要。确定研究格局对于控制和消除利什曼病的计划至关重要。它将有助于参考已进行的研究，确定是否需要系统评价，并有助于确定未来的研究方向。
本方案是根据 JBI 范围审查方法学小组关于进行范围审查的指南以及 PRISMA-ScR 报告范围审查指南制定的。将搜索以下数据库：PubMed、Embase 通过 Embase.com、Web of Science Core Collection、Cochrane 中心、全球医学索引、ClinicalTrials.gov、泛非临床试验登记处和 PROSPERO。可能未在上述系统中索引的本地出版文献将通过熟悉该环境的团队成员确定。将使用纳入-排除标准在摘要-标题屏幕和全文屏幕中对每个记录进行双重和盲法审查。纳入的文章必须深入讨论埃塞俄比亚的利什曼病。提取的数据将包括研究主题、研究类型以及在制定的代码本中定义的类别和子类别，以及利什曼原虫的类型、发表年份、资金来源和引用次数。结果将用汇总统计数据报告。
个人同意和伦理批准不适用。我们计划将我们的发现传播给适当的利益相关者。
